Prevalence and clinical relevance of familial hypercholesterolemia-causing mutations in Germany

Résumé fourni par la source

Abstract Background Familial hypercholesterolemia (FH) is a monogenic disease characterized by pathogenic mutations in genes involved in low-density lipoprotein cholesterol (LDL-C) metabolism. Optimal strategies for identifying FH in the general population are still unknown. Objective To assess the prevalence of genetic FH (genFH) in a contemporary population-based sample of adult Hamburg residents and to evaluate its association with hypercholesterolemia phenotype. Methods In 7,373 participants of the population-based a City Health Study (HCHS) the FH genes LDLR, APOB, PCSK9, LDLRAP1, and APOE were analyzed to identify genFH, based on short-read whole-genome sequencing. LDL-C concentrations were adjusted for intake and intensity of lipid-lowering medication and categorized using the following thresholds: ≥130/≥160/≥190 mg/dL. Severe hypercholesterolemia was defined by LDL-C ≥190 mg/dL. Results Among 7,373 adults, median age was 62.0 (quartiles 54.0-69.0) years, and 49.1% of these were women. Twenty-three individuals had heterozygous genFH (prevalence 0.31%; 95%CI: 0.21% to 0.47% [corresponding to 1:321]), all caused by mutations in the LDLR gene. Median treatment-corrected LDL-C was higher in subjects with genFH (191 mg/dL, quartiles 149-210 mg/dL) compared to 128 mg/dL (quartiles 105-153 mg/dL) in those without genFH. Severe hypercholesterolemia was observed in 476 of 7,275 (6.5%) subjects with available LDL-C values. Of those, only 2.3% (n=11) were positive for genFH. Moreover, 9.1% of carriers of FH-causing variants had LDL-C values below 130 mg/dL, 32.8% below 160 mg/dL and only 50% of subjects with genFH had severe hypercholesterolemia (Table). Applying a phenotypic LDL-C threshold of ≥190 mg/dL, ≥160 mg/dL and ≥130 mg/dL to screen for genFH would results in numbers needed to screen of 43, 99 or 174, respectively. Conclusion The prevalence of genetically verified FH in this contemporary German population-based cohort was very similar to the worldwide prevalence of FH (0.31% versus 0.32%, respectively). Only half of the adult individuals with genFH had severe hypercholesterolemia, and only (2.3%) of individuals with LDL-C ≥190 mg/dL had genFH. More robust evidence of genotype-phenotype associations of FH mutations is needed to accurately infer at-risk individuals from genetic screening. Two first and two last auhors contributed equally to this work.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.